IP Library Granted Patent US 11,042,980
Granted Patent B1
US 11,042,980 · App. 17/138,821 · Granted Jun 22, 2021

Method and apparatus for using quantative and qualitative data from medical imaging examinations for precise dosing regimen

Inventors: Robert Edwin Douglas (Winter Park, FL); David Byron Douglas (Winter Park, FL); Kathleen Mary Douglas (Winter Park, FL)
G06T7/0012A61B6/481B33Y30/00G01R33/5601G06N20/00G06T7/11G06T7/62G16H50/30G06T2207/30004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,042,980
App. No.
17/138,821
Granted
Jun 22, 2021
Kind
B1
Abstract

This patent includes a method for utilizing imaging biomarkers to improve pharmacologic dosing strategies. Specifically, biomarker specific CT and MRI examination protocols are disclosed. Dose adjustments based on imaging biomarkers are discussed. Longitudinal analysis of imaging biomarkers is disclosed assess effectiveness of pharmacotherapy and dosing strategies thereof. Finally, manufacturing of a combination pill with day-to-day variations of drug quantities is disclosed.

Claims (47)

1. A method comprising:

receiving a pre-image biomarker adjusted dose (pre-IBAD) of a pharmaceutical wherein said pre-IBAD is an initial dose of said pharmaceutical;

performing a dose-adjustment wherein said performing said dose-adjustment comprises:

analyzing at least one imaging biomarker from a medical imaging examination of a patient at a first time point

wherein said medical imaging examination comprises an imaging biomarker specific protocol

wherein said imaging biomarker specific protocol comprises at least one of the group consisting of:

a CT scan wherein said CT scan comprises a low dose scan with a high spatial resolution and low contrast resolution that meet a threshold within a prespecified range to delineate boundaries of organ(s); and

an MRI scan wherein said MRI scan comprises a low dose scan with a high spatial resolution and low contrast resolution that meet a threshold within a prespecified range to delineate boundaries of organ(s);

wherein image(s) from said medical imaging examination comprise said at least one imaging biomarker, and

wherein said at least one imaging biomarker comprises quantitative data based on organs(s) in said medical imaging examination;

wherein said quantitative data based on organ(s) in said medical imaging examination is used to generate health status(es) of said organ(s);

adjusting said pre-IBAD of said pharmaceutical via an artificial intelligence algorithm to generate a post-image biomarker adjusted dose (post-IBAD) wherein said artificial intelligence algorithm utilizes said health status(es) of said organ(s); and

sending said post-IBAD of said pharmaceutical to a physician.

2. The method of claim 1 further comprising wherein said at least one imaging biomarker comprises at least one of the group consisting of:

categorical variable(s);

ordinal variable(s);

binary variable(s); and

continuous variable(s).

3. The method of claim 1 further comprising wherein said at least one imaging biomarker is characterized via an artificial intelligence algorithm.

4. The method of claim 1 further comprising adjusting said dose based on activities of daily living wherein said activities of daily living comprise at least one of the group consisting of:

number of steps walked; and

sleep hours.

5. The method of claim 1 further comprising wherein said at least one imaging biomarker comprises at least one a pathologic condition.

6. The method of claim 1 further comprising wherein said at least one imaging biomarker comprises a binary variable used to characterize an anatomic structure as either normal or as abnormal.

7. The method of claim 1 further comprising analyzing an imaging biomarker longitudinally over at least two different imaging examinations to determine effectiveness of pharmacotherapy.

8. The method of claim 1 further comprising adjusting said dose of said pharmaceutical based on interval change of said at least one imaging biomarker.

9. The method of claim 1 further comprising:

predicting a time of an adverse health event; and

adjusting said dose of said pharmaceutical based on predicting said time of said adverse health event.

10. The method of claim 1 further comprising adjusting a dose of a pharmaceutical based on at least one of the group consisting of:

a photograph from a dermatologic finding;

data collected from an internet of things; and

a laboratory finding.

11. The method of claim 1 further comprising predicting a pain level based on said imaging biomarker.

12. A non-transitory computer readable information storage medium having computer-executable instructions which, when executed by a computing device, cause the computing device to perform the operations of:

receiving a pre-image biomarker adjusted dose (pre-IBAD) of a pharmaceutical wherein said pre-IBAD is an initial dose of said pharmaceutical;

performing a dose-adjustment wherein said performing said dose-adjustment comprises:

analyzing at least one imaging biomarker from a medical imaging examination of a patient at a first time point

wherein said medical imaging examination comprises an imaging biomarker specific protocol

wherein said imaging biomarker specific protocol comprises at least one of the group consisting of:

a CT scan wherein said CT scan comprises a low dose scan with a high spatial resolution and low contrast resolution that meet a threshold within a prespecified range to delineate boundaries of organ(s); and

an MRI scan wherein said MRI scan comprises a low dose scan with a high spatial resolution and low contrast resolution that meet a threshold within a prespecified range to delineate boundaries of organ(s);

wherein image(s) from said medical imaging examination comprise said at least one imaging biomarker, and

wherein said at least one imaging biomarker comprises quantitative data based on organs(s) in said medical imaging examination;

wherein said quantitative data based on organ(s); in said medical imaging examination is used to generate health status(es) of said organ(s);

adjusting said pre-IBAD of said pharmaceutical via an artificial intelligence algorithm to generate a post-image biomarker adjusted dose (post-IBAD) wherein said artificial intelligence algorithm utilizes said health status(es) of said organ(s); and

sending said post-IBAD of said pharmaceutical to a physician.

Continuity (3)
Continuation In Part 16939192 · Jul 27, 2020
Provisional Application 62956330 · Jan 2, 2020
Provisional Application 62957300 · Jan 5, 2020
Cited By (1)
US 12,290,379